Prestige Consumer Healthcare Inc
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; various… Read more
Prestige Consumer Healthcare Inc (PBV) - Net Assets
Latest net assets as of September 2025: €1.82 Billion EUR
Based on the latest financial reports, Prestige Consumer Healthcare Inc (PBV) has net assets worth €1.82 Billion EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€3.44 Billion) and total liabilities (€1.62 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.82 Billion |
| % of Total Assets | 53.02% |
| Annual Growth Rate | 11.33% |
| 5-Year Change | 35.09% |
| 10-Year Change | 146.51% |
| Growth Volatility | 13.02 |
Prestige Consumer Healthcare Inc - Net Assets Trend (2014–2025)
This chart illustrates how Prestige Consumer Healthcare Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Prestige Consumer Healthcare Inc (2014–2025)
The table below shows the annual net assets of Prestige Consumer Healthcare Inc from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | €1.83 Billion | +10.86% |
| 2024-03-31 | €1.66 Billion | +14.37% |
| 2023-03-31 | €1.45 Billion | -8.27% |
| 2022-03-31 | €1.58 Billion | +16.15% |
| 2021-03-31 | €1.36 Billion | +16.00% |
| 2020-03-31 | €1.17 Billion | +6.86% |
| 2019-03-31 | €1.10 Billion | -7.02% |
| 2018-03-31 | €1.18 Billion | +43.29% |
| 2017-03-31 | €822.55 Million | +10.51% |
| 2016-03-31 | €744.34 Million | +18.60% |
| 2015-03-31 | €627.62 Million | +11.41% |
| 2014-03-31 | €563.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Prestige Consumer Healthcare Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 943.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €1.56 Billion | 84.79% |
| Other Components | €279.10 Million | 15.21% |
| Total Equity | €1.83 Billion | 100.00% |
Prestige Consumer Healthcare Inc Competitors by Market Cap
The table below lists competitors of Prestige Consumer Healthcare Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ningbo Sanxing Medical Electric Co Ltd
SHG:601567
|
$2.54 Billion |
|
Sulzer Ltd
PINK:SULZF
|
$2.54 Billion |
|
Tav Havalimanlari Holding AS
PINK:TAVHY
|
$2.54 Billion |
|
Silicon Motion Technology Corporation
F:S9M
|
$2.54 Billion |
|
L&T Finance Limited
NSE:LTF
|
$2.54 Billion |
|
Alupar Investimento SA
SA:ALUP11
|
$2.54 Billion |
|
Kokuyo Co., Ltd.
PINK:KUKYF
|
$2.53 Billion |
|
Mineral Res
PINK:MALRY
|
$2.53 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Prestige Consumer Healthcare Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,655,084,000 to 1,834,897,000, a change of 179,813,000 (10.9%).
- Net income of 214,605,000 contributed positively to equity growth.
- Share repurchases of 51,509,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €214.60 Million | +11.7% |
| Share Repurchases | €51.51 Million | -2.81% |
| Other Changes | €16.72 Million | +0.91% |
| Total Change | €- | 10.86% |
Book Value vs Market Value Analysis
This analysis compares Prestige Consumer Healthcare Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.35x to 1.40x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | €15.53 | €52.00 | x |
| 2018-03-31 | €22.22 | €52.00 | x |
| 2019-03-31 | €21.16 | €52.00 | x |
| 2020-03-31 | €23.38 | €52.00 | x |
| 2021-03-31 | €27.21 | €52.00 | x |
| 2022-03-31 | €31.38 | €52.00 | x |
| 2023-03-31 | €29.12 | €52.00 | x |
| 2024-03-31 | €33.22 | €52.00 | x |
| 2025-03-31 | €37.06 | €52.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Prestige Consumer Healthcare Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.70%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.86%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.85x
- Recent ROE (11.70%) is above the historical average (10.73%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 12.89% | 12.16% | 0.33x | 3.19x | €16.28 Million |
| 2015 | 12.47% | 10.95% | 0.27x | 4.21x | €15.50 Million |
| 2016 | 13.42% | 12.39% | 0.27x | 3.96x | €25.47 Million |
| 2017 | 8.44% | 7.87% | 0.23x | 4.76x | €-12.86 Million |
| 2018 | 28.81% | 32.61% | 0.28x | 3.19x | €221.71 Million |
| 2019 | -3.27% | -3.67% | 0.28x | 3.14x | €-145.38 Million |
| 2020 | 12.15% | 14.77% | 0.27x | 3.00x | €25.18 Million |
| 2021 | 12.12% | 17.46% | 0.28x | 2.52x | €28.85 Million |
| 2022 | 13.02% | 18.90% | 0.30x | 2.33x | €47.62 Million |
| 2023 | -5.69% | -7.30% | 0.34x | 2.32x | €-227.01 Million |
| 2024 | 12.65% | 18.60% | 0.34x | 2.00x | €43.83 Million |
| 2025 | 11.70% | 18.86% | 0.33x | 1.85x | €31.12 Million |
Industry Comparison
This section compares Prestige Consumer Healthcare Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Prestige Consumer Healthcare Inc (PBV) | €1.82 Billion | 12.89% | 0.89x | $2.54 Billion |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |